Alacrita Strengthens Cambridge, MA Team to Advise Clients on Clinical Development Strategy, Planning and Operations

CAMBRIDGE, Massachusetts and LONDON, January 8, 2015 /PRNewswire/ --

Appoints William Slichenmyer as Associate Partner 

Alacrita, the rapidly growing, transatlantic life sciences consulting firm, today announced that it has appointed William (Bill) Slichenmyer as an Associate Partner based in its Cambridge, MA office.

The move strengthens Alacrita's Cambridge team and in particular consolidates its position as a leading provider of expert advice to life science companies looking to develop and launch novel therapeutic agents. For over 20 years Bill has held leadership and executive roles in large and small pharma companies including AVEO Oncology, Pfizer, Parke-Davis, Bristol-Myers Squibb, Merrimack Pharmaceuticals and Hybridon.  His responsibilities in these roles have spanned across clinical development, medical affairs and regulatory affairs, from preclinical development through post-marketing trials.  Bill earned his MD degree at Case Western Reserve University.  He received specialty training in internal medicine at the University of Texas Health Science Center in San Antonio and medical oncology at the Johns Hopkins Oncology Center.  He earned the ScM degree in Clinical Investigation at the Johns Hopkins University.

Bill joins a growing team of specialists at Alacrita who have distinguished track records of starting and growing life science businesses. Alacrita is supported by a team of Associates across Europe and the U.S., all of whom are carefully selected for their deep life science industry experience and expertise. The firm supports clients with life science strategy, due diligence and operational support.

Bill Slichenmyer said "I am delighted to be joining the Alacrita team, which has an impressive track record of advising client organizations in the life sciences. The pace of innovation in our industry is accelerating while the regulatory and payer environments are evolving rapidly. I look forward to engaging with our clients on their drug development and commercialization efforts."

Rob Johnson, Partner at Alacrita, said: "We are delighted to welcome Bill to Alacrita as we build a best-in-class consulting practice to help companies with strategy, planning and operational support. Bill is an experienced executive and his expertise is rooted in reality, having first-hand experience of developing numerous anticancer drugs. He has deep and broad knowledge of the pharmaceutical industry and a sound understanding of the challenges faced by senior management. He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry."

Notes to Editors 

About Alacrita 

Alacrita is a rapidly growing, transatlantic management consulting firm providing expertise-based services to the pharmaceutical, biotechnology, medical devices and life science sectors. The firm is supported by an unrivalled team of experts who operate across the spectrum of life sciences. They combine extensive international industry experience (strategic, technical and commercial), broad functional capabilities and a track record of success across the industry.

Alacrita Europe:

London BioScience Innovation Centre
2 Royal College Street
London, NW1 0NH
Tel: +44-207-691-4915

Alacrita US:

One Broadway, 14th floor
Kendall Square
Cambridge, MA 02142
Tel: +1-617-758-4119
http://www.alacrita.com

For further information, please contact:
At Alacrita US:
Rob Johnson, Partner
rjohnson@alacrita.com
William Slichenmyer
wslichenmeyer@alacrita.com

At Alacrita Europe:
Anthony Walker, Partner
awalker@ alacrita.com
Simon Turner, Partner
sturner@alacrita.com